Tocilizumab

Generic Name
Tocilizumab
Brand Names
Actemra, RoActemra, Tyenne, Tofidence
Drug Type
Biotech
Chemical Formula
-
CAS Number
375823-41-9
Unique Ingredient Identifier
I031V2H011
Background

Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflamm...

Indication

Tocilizumab is indicated to treat moderate to severe rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.
...

Associated Conditions
Coronavirus Disease 2019 (COVID‑19), Cytokine Release Syndrome caused by CAR-T Cell Therapy, Giant Cell Arteritis (GCA), Juvenile Chronic Polyarthritis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis (SJIA), Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), Active systemic Juvenile idiopathic arthritis, Severe, active Rheumatoid arthritis
Associated Therapies
Monotherapy
Clinical Trials
Related News
medigatenews.com
·

Celltrion presents phase III data supporting biosimilarity of CT-41 and CT-P47 at ACR

Celltrion presented Phase III RCT data for biosimilars CT-P41 and CT-P47 at ACR Convergence 2024, showing comparable efficacy and safety profiles to reference drugs denosumab and tocilizumab in treating osteoporosis and rheumatoid arthritis, respectively.
centerforbiosimilars.com
·

EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data

EU approves 2 aflibercept biosimilars; Biosimilars Canada launches #SaveBigWithBiosimilars campaign; Celltrion presents positive data for denosumab and tocilizumab biosimilars.
businesskorea.co.kr
·

Celltrion Announces Phase 3 Results of Actemra and Prolia Biosimilars at U.S. Conference

Celltrion disclosed global Phase 3 data for biosimilars CT-P47 and CT-P41 at the 2024 ACR Annual Meeting, showing efficacy and safety. CT-P47's 52-week trial on RA patients and CT-P41's 78-week trial on osteoporosis patients met equivalence criteria. Both biosimilars are under approval worldwide.
centerforbiosimilars.com
·

Samsung Bioepis Report Showcases Adalimumab Biosimilar Growth in Market Share

Adalimumab biosimilars' market share rose from 2% to 22% in early 2024, driven by private label brands. The FDA approved 61 biosimilars across 17 molecules, with 41 launched in the US. Biosimilars' average sales prices decreased by 53% over 5 years. Major PBMs like CVS Caremark and Evernorth are adding biosimilars to formularies. Adalimumab biosimilars offer multiple pricing options, with some at 85-86% less than Humira. Biosimilars saved payers $1.6 PMPM, with potential for further growth.
finance.yahoo.com
·

Fresenius Kabi wins FDA approval for Stelara biosimilar Otulfi

Fresenius Kabi and Formycon receive FDA approval for Otulfi, a Stelara biosimilar, for treating Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis, and active psoriatic arthritis. Otulfi is the fourth Stelara biosimilar approved in the US, following Amgen’s Wezlana, Alvotech and Teva’s Selarsdi, and Samsung Bioepis and Sandoz’s Pyzchiva. Stelara sales are expected to drop to $1.2bn by 2030 due to biosimilar competition.
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy